ESN Cleer

ESN Cleer, established in 2017 and headquartered in Melbourne, Australia, specializes in the development of innovative medical devices for heart disease prevention. The company's flagship product is a handheld device that employs nanotechnology-enabled biomarker sensors to detect cardiovascular diseases using saliva samples. ESN Cleer's mission is to transform the way specific segments of cardiomyopathy, a leading cause of heart failure, are addressed. The company focuses on repurposing drugs for rare diseases without specific treatments, aiming to improve both the mortality risk and quality of life for affected individuals.